Infigratinib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Infigratinib
Accession Number
DB11886
Type
Small Molecule
Groups
Investigational
Description

Infigratinib is under investigation for the treatment of Head and Neck Squamous Cell Carcinoma.

Structure
Thumb
Synonyms
Not Available
External IDs
BGJ 398 / BGJ-398 / BGJ398
Product Ingredients
IngredientUNIICASInChI Key
Infigratinib acetate03D0789NYP1310746-17-8XHCQHOGMMJKLRU-UHFFFAOYSA-N
Infigratinib hydrochlorideWY8VD4RV771310746-15-6VBAIJSJSFCXDJB-UHFFFAOYSA-N
Infigratinib mesylateE223Z0KWCC1310746-12-3BXJJFNXYWJLBOS-UHFFFAOYSA-N
Infigratinib phosphate58BH47BV6S1310746-10-1GUQNHCGYHLSITB-UHFFFAOYSA-N
Categories
UNII
A4055ME1VK
CAS number
872511-34-7
Weight
Average: 560.475
Monoisotopic: 559.186543307
Chemical Formula
C26H31Cl2N7O3
InChI Key
QADPYRIHXKWUSV-UHFFFAOYSA-N
InChI
InChI=1S/C26H31Cl2N7O3/c1-5-34-10-12-35(13-11-34)18-8-6-17(7-9-18)31-21-15-22(30-16-29-21)33(2)26(36)32-25-23(27)19(37-3)14-20(38-4)24(25)28/h6-9,14-16H,5,10-13H2,1-4H3,(H,32,36)(H,29,30,31)
IUPAC Name
3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)-1-methylurea
SMILES
CCN1CCN(CC1)C1=CC=C(NC2=CC(=NC=N2)N(C)C(=O)NC2=C(Cl)C(OC)=CC(OC)=C2Cl)C=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Darbepoetin alfaThe risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Infigratinib.
ErythropoietinThe risk or severity of Thrombosis can be increased when Erythropoietin is combined with Infigratinib.
Methoxy polyethylene glycol-epoetin betaThe risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Infigratinib.
PeginesatideThe risk or severity of Thrombosis can be increased when Peginesatide is combined with Infigratinib.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
53235510
PubChem Substance
347828222
ChemSpider
26333103
BindingDB
50355393
ChEBI
63451
ChEMBL
CHEMBL1852688
HET
07J
PDB Entries
3tt0

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentAdvanced Solid Tumors With Alterations of FGFR1, 2 and or 3 / Advanced Solid Tumors With Alterations of FGFR1, 2 and/or 3 / Advanced Solid Tumors With FGFR1 Amplication / Advanced Solid Tumors With FGFR2 Amplication / Advanced Solid Tumors With FGFR3 Mutation / Bladder Cancer With FGFR3 Mutation or Fusion / Squamous Lung Cancer With FGFR1 Amplification1
1CompletedTreatmentAdvanced Solid Tumors / Metastatic Solid Tumors1
1CompletedTreatmentTumor With Alterations of the FGF-R1
1WithdrawnTreatmentCancer of Cervix / Tumors1
1, 2CompletedTreatmentAdvanced Gastrointestinal Stromal Tumor (GIST)1
1, 2Not Yet RecruitingTreatmentRenal Pelvis and Ureter Urothelial Carcinoma1
1, 2WithdrawnTreatmentAdenocarcinoma of the Pancreas / Colon Adenocarcinoma / Pancreatic Adenocarcinoma Metastatic / Pancreatic Ductal Adenocarcinoma / Rectal Adenocarcinoma / Stage III Pancreatic Cancer / Stage IIIA Colon Cancer / Stage IIIA Rectal Cancer / Stage IIIB Colon Cancer / Stage IIIB Rectal Cancer / Stage IIIC Colon Cancer / Stage IIIC Rectal Cancer / Stage IV Pancreatic Cancer / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Rectal Cancer1
2Active Not RecruitingTreatmentMelanoma1
2CompletedTreatmentRecurrent Glioblastoma or Other Glioma Subtypes1
2Not Yet RecruitingTreatmentAdvanced Malignant Solid Neoplasm / Cholangiocarcinomas / Metastatic Malignant Solid Neoplasm / Refractory Malignant Solid Neoplasm1
2RecruitingTreatmentAdvanced Cholangiocarcinoma / FGFR2 Gene Mutation1
2RecruitingTreatmentOncogenic Osteomalacia / Tumor-Induced Osteomalacia1
2TerminatedTreatmentFGFR Gene Amplification / FGFR1 Gene Amplification / FGFR2 Gene Amplification / FGFR2 Gene Mutation / FGFR3 Gene Mutation / Head and Neck Squamous Cell Carcinoma (HNSCC) / Human Papillomavirus Infections / Recurrent Head and Neck Carcinoma / Recurrent Nasopharynx Carcinoma / Recurrent Oropharyngeal Squamous Cell Carcinoma1
2TerminatedTreatmentMalignancies, Hematologic / Tumors, Solid1
3Not Yet RecruitingTreatmentUpper Tract Urothelial Carcinomas / Urothelial Bladder Cancer1
3RecruitingTreatmentAdvanced Cholangiocarcinoma / FGFR2 Gene Mutation1
Not AvailableActive Not RecruitingTreatmentBladder Cancers / Non-Muscle-Invasive Urothelial Carcinoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0299 mg/mLALOGPS
logP4.68ALOGPS
logP4.78ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)9.98ChemAxon
pKa (Strongest Basic)8.23ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area95.09 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity152.71 m3·mol-1ChemAxon
Polarizability58.51 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazinanes
Sub Class
Piperazines
Direct Parent
Phenylpiperazines
Alternative Parents
N-arylpiperazines / Dimethoxybenzenes / N-phenylureas / Methoxyanilines / Dialkylarylamines / Dichlorobenzenes / Phenoxy compounds / Anisoles / Alkyl aryl ethers / N-alkylpiperazines
show 13 more
Substituents
N-arylpiperazine / Phenylpiperazine / Dimethoxybenzene / M-dimethoxybenzene / N-phenylurea / Methoxyaniline / 1,3-dichlorobenzene / Phenol ether / Methoxybenzene / Tertiary aliphatic/aromatic amine
show 35 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
N-arylpiperazine, ureas, aminopyrimidine, dichlorobenzene, N-alkylpiperazine (CHEBI:63451)

Drug created on October 20, 2016 14:57 / Updated on December 02, 2019 09:13